Although about two thirds of patients have multiple mutations, mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, according to Markman and colleagues. The presence of one mutation to the exclusion of another can influence response to targeted therapy.
On the other hand, PIK3CA mutations frequently coexist with EGFR/KRAS mutations, per Wang and colleagues. The poor prognosis of patients with single PIK3CA mutation in NSCLC and the prognostic value of PIK3CA mutation in EGFR/KRAS wild-type subgroup suggest that the distinct mutation status of PIK3CA gene should be determined for individual therapeutic strategies in NSCLC.
Learn more about genetic mutations in NSCLC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer - Medscape - Aug 22, 2022.